Speakers

Expand/Collapse

Alejandra Raimondi
Vice President Biological Sciences
Epizyme

Day One

Wednesday, July 27

9:45 am | Identifying Novel Targets for Epigenetic Drug Discovery & Development to Accelerate Pipeline Decision Making

9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?

Alon Goren
Assistant Professor
University of San Diego California (UCSD)

Day One

Wednesday, July 27

10:15 am | Improvements to ChIP-seq by Using Automation & Spike-in Normalization Approaches

Day Two

Thursday, July 28

2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance

Asad Taherbhoy
Director of Drug Discovery
Foghorn Therapeutics

Day One

Wednesday, July 27

9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?

Day Two

Thursday, July 28

10:00 am | Targeting Transcription Factor-BAF Interactions in Cancer

Ayman El-Guindy
Chief Scientific Officer
Viracta Therapeutics

Day Two

Thursday, July 28

12:00 pm | Considering Combinatorial Approaches: Using an Antiviral Prodrug to Target EBV+ Malignancies

Claes Wahlestedt
Associate Dean & Center Director for Therapeutic Innovation; Chief Scientific Officer
University of Miami Miller School of Medicine; Epigenetix

Day One

Wednesday, July 27

11:45 am | Exploring the Discovery & Development of an Oral Trispecific Cancer Drug

Day Two

Thursday, July 28

2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance

David Bumcrot
Chief Scientific Officer
CAMP4 Therapeutics

Day Two

Thursday, July 28

11:00 am | Regulating Gene Expression by Targeting Regulatory RNAs: A Novel Therapeutic Approach

Henry Long
Scientific Director Center for Functional Cancer Epigenetics
Dana Farber Cancer Institute

Day Two

Thursday, July 28

1:30 pm | Studying Neuroendocrine Transdifferentiation as a Mechanism of Drug Resistance

Isaac Klein
Chief Scientific Officer
Dewpoint Therapeutics

Day One

Wednesday, July 27

8:55 am | Chair Opening Remarks

Jacob Berchuck
Medical Oncologist
Dana Farber Cancer Institute

Day Two

Thursday, July 28

9:30 am | Opportunities for non-invasive cancer detection and classification through epigenetic analysis of cell-free DNA

Kirk Tanner
Chief Scientific Officer
National Brain Tumor Society

Day One

Wednesday, July 27

1:45 pm | Detailing the Opportunities for Epigenetic Drug Discovery & Development in CNS Tumors to Inform Pipeline Decision Making

Kristen JensenPergakes
Associate Research Fellow
Pfizer

Day One

Wednesday, July 27

11:15 am | SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Laura Poling
Director of Biology
C4 Therapeutics

Day Two

Thursday, July 28

11:30 am | CFT8634, a Potent & Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers

Matthew Oser
Assistant Professor of Medicine Dana Farber Cancer Institute
Harvard Medical School

Day One

Wednesday, July 27

3:15 pm | Spearheading CRISPR/Cas9 Screening to Identity Genes Necessary for LSD1 to Maintain the Neuroendocrine Identify of Small Cell Lung Cancer

Paloma Cejas
Assistant Director for Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute

Day Two

Thursday, July 28

9:00 am | Evaluating Current Exploration into the Single Cell Space to Precisely Understand Epigenetic Behaviour

2:00 pm | PANEL DISCUSSION: Let’s Talk About Epigenetic Drug Resistance

Peter Atadja
Co-Founder & Chief Scientific Officer
K36 Therapeutics

Day One

Wednesday, July 27

9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?

Philipp Mews
Co-Founder
EpiVario

Day One

Wednesday, July 27

2:45 pm | Developing Small-Molecule Drugs for Epigenetic Treatments of Psychiatric Disorders

Rich Bennett
Assistant Professor
University of Florida

Day One

Wednesday, July 27

1:15 pm | Leveraging CRISPR: Identification of Essential Proliferation & Trametinib Resistance Mechanisms in Uveal Melanoma

9:00 am | PANEL DISCUSSION: 2022 & Beyond: Where Do We See the Epigenetics Drug Discovery & Development Landscape Over the Next 5 Years?

Shikhar Sharma
Research Fellow
Pfizer

Day Two

Thursday, July 28

2:45 pm | Translating Established Targets: Potent anti-Tumor Activity of a KAT6A/KAT6B Inhibitor PF-9363/CTx-648 in KAT6A dysregulated ER+ Breast Cancer

Steven Fruchtman
President & Chief Executive Officer
Onconova Therapeutics

Day Two

Thursday, July 28

8:55 am | Chair’s Opening Remarks